Nathalie Toublanc - Concepedia

Author

Nathalie Toublanc

UCB Pharma (Belgium)

Also Known As

M Troenaru, N TOUBLANC, N Toublanc, N. Toublanc, Nathalie Toublanc, Teil, Marie

Publications

860

Citations

H-Index

Concepts

All Affiliations

UCB Pharma (Belgium)Eli Lilly (United States)UCB Pharma (Japan)UCB Pharma (United States)Ziekenhuisnetwerk Antwerpen Stuivenberg

About

Nathalie Toublanc is an author at UCB Pharma (Belgium) specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	267
2	Pharmacology	6	6	267
3	Neurology	2	2	51
4	Nephrology	1	1	19
5	Epilepsy	1	1	19

Nathalie Toublanc

Publications

780

Citations

H-Index

Page 1

	Year	Citations
Levetiracetam Intravenous Infusion: A Randomized, Placebo‐controlled Safety and Pharmacokinetic Study Steven Ramael, Agnès Daoust, Christian Otoul, Epilepsia	2006	191
Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study Megan E. B. Clowse, Frauke Förger, Caroline Hwang, Annals of the Rheumatic Diseases	2017	172
Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects Steven Ramael, Florimond De Smedt, Nathalie Toublanc, Clinical Therapeutics Single-dose BioavailabilityTherapeutic Drug MonitoringHealthy SubjectsLevetiracetam Intravenous InfusionPharmacology	2006	118
Talampanel, a New Antiepileptic Drug: Single‐ and Multiple‐dose Pharmacokinetics and Initial 1‐Week Experience in Patients with Chronic Intractable Epilepsy Yvonne Langan, Richard Lucas, Haley Jewell, Epilepsia	2003	75
Retrospective Population Pharmacokinetic Analysis of Levetiracetam in Children and??Adolescents with Epilepsy Nathalie Toublanc, Maria Laura Sargentini‐Maier, Brigitte Lacroix, Clinical Pharmacokinetics Drug SafetyMedicinePediatricsNeuropharmacologyPharmacotherapy	2008	58
Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements Georg Hempel, Mats O. Karlsson, Dinesh P. de Alwis, Clinical Pharmacology & Therapeutics	1998	47
Multiple‐Dose Plasma Pharmacokinetic and Safety Study of LY450108 and LY451395 (AMPA Receptor Potentiators) and Their Concentration in Cerebrospinal Fluid in Healthy Human Subjects S. S. Jhee, Amy S. Chappell, Victoria Zarotsky, The Journal of Clinical Pharmacology Healthy SubjectsCsf ConcentrationsNeurophysiologyMedicineCerebrospinal Fluid	2006	32
Development of an Integrated Population Pharmacokinetic Model for Oral Levetiracetam in Populations of Various Ages and Ethnicities Nathalie Toublanc, Brigitte Lacroix, Junichi Yamamoto Drug Metabolism and Pharmacokinetics	2013	28
Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects Nathalie Toublanc, Xinlu Du, Yun Liu, Clinical Drug Investigation Drug SafetyOral TabletsLevetiracetam Intravenous InfusionHealthy Chinese SubjectsPharmacology	2015	21
Levetiracetam Pharmacokinetics in Japanese Subjects with Renal Impairment Junichi Yamamoto, Nathalie Toublanc, Yuji Kumagai, Clinical Drug Investigation UrologyLevetiracetam PharmacokineticsMedicineChronic Kidney DiseasePharmacotherapy	2014	19

Page 1